Alkem Laboratories has appointed Dr Amrut Naik as its Chief Executive Officer and Key Managerial Personnel, effective 11 November 2026. The board of directors approved the appointment at a meeting held on 3 November 2026, following a recommendation from its Nomination and Remuneration Committee. According to Alkem’s filing, his appointment will continue for the duration of his employment with the company.

Update, 20 November 2026: the appointment has now taken effect, and C-Suite India covered it on LinkedIn on 19 November 2026. The move is tracked in our Leadership Moves database.

Who is Amrut Naik?

Naik brings more than 25 years of experience in the pharmaceutical industry, having held leadership positions at Zydus Group and Lupin Pharmaceuticals, among others. He most recently served as President of Zydus Group, a position he held from July 2016 to November 2026 — over ten years at the top of one of India’s large drugmakers, most recently leading its international business.

Before Zydus, Naik was Managing Director of Lupin Pharmaceuticals in Mexico from July 2013 to July 2016. Earlier still, he served as Senior Vice President at Lupin between July 2008 and June 2013, where he led the company’s business in emerging markets and worked on business acquisitions, joint ventures and strategic alliances across multiple continents. He has also held leadership roles at Emcure and Ranbaxy.

His professional profile states that he has over 15 years of experience in chief executive-level roles, overseeing business development, sales and marketing, technical operations and mergers and acquisitions, and that he has closed five cross-border deals and established two joint ventures. His experience spans branded formulations, generics, active pharmaceutical ingredients, biologics, vaccines, specialty products and innovation-led portfolios.

The academic and industry record

Naik holds a PhD (Tech) in Pharmacology, a Master’s degree in Pharmaceutical Science and a Bachelor’s degree in Pharmaceutical Science. Beyond his corporate roles, he served as Chairperson of the Federation of Indian Chambers of Commerce and Industry (FICCI) Regional Council between 2023 and 2025, and is a member of FICCI’s National Executive Committee.

That combination — a doctorate in pharmacology, a decade running a large pharma group, and a spell leading a business in Mexico — is unusual among Indian pharma chiefs, who more often come up through domestic sales or finance. Alkem has hired a leader whose career has been built across international markets, acquisitions and alliances.

The context at Alkem

The appointment ends a search that has run since June. ET Pharma reports that Alkem has seen a series of senior management exits over the past few months, beginning with the departure of then-CEO Vikas Gupta in June, followed by the resignation of Chief Financial Officer Nitin Agarwal, who stepped down to pursue other professional opportunities. Gupta’s exit, the report notes, came amid mounting pressure in Alkem’s trade generics segment in its stronghold domestic business.

Alkem is expected to announce its second-quarter earnings later in November. Naik therefore takes charge days before the market gets its next formal read on the business — and his first earnings call will be watched for how he frames the domestic business, where the pressure has been felt.

What this signals

Alkem has chosen an outsider with deep operating experience over an internal promotion, and it has chosen international experience at a moment when its domestic trade generics business is under pressure. The logic is legible: a chief executive who has run international businesses, closed cross-border deals and built joint ventures is a bet on diversification — on growing the parts of Alkem that are not the pressured domestic trade channel.

The appointment is also a clean break. A five-month gap at the top, a departed CFO, and a new chief executive arriving the same week as results season make this a reset rather than a handover. The first test is not strategic but practical: steady the domestic business while the new chief finds his feet.

Related reading: another healthcare leadership appointment from the same season — Dr Ritu Garg to lead Apollo Hospitals as CEO.

FAQs

Who is Alkem Laboratories’ new CEO? Dr Amrut Naik, appointed Chief Executive Officer and Key Managerial Personnel, effective 11 November 2026.

When was Amrut Naik’s appointment approved? By Alkem’s board of directors on 3 November 2026, following a recommendation from its Nomination and Remuneration Committee.

What did Amrut Naik do at Zydus Group? He was President of Zydus Group from July 2016 to November 2026, most recently leading its international business.

What is Amrut Naik’s background? He has more than 25 years of experience in the pharmaceutical industry, including as Managing Director of Lupin Pharmaceuticals in Mexico and Senior Vice President at Lupin. He holds a PhD (Tech) in Pharmacology.

Who did Amrut Naik succeed at Alkem? Vikas Gupta, Alkem’s previous CEO, who departed in June 2026.